Basilea Pharmaceutica Ltd., of Basel, Switzerland, said it started a phase I/IIa study testing its oral formulation of BAL101553, a microtubule-destabilizing small molecule designed to act as tumor checkpoint controller as it promotes tumor cell death through activation of an important checkpoint in cell proliferation.